Placebo-controlled study of pramiracetam in Young males with memory and cognitive problems resulting from head injury and anoxia

Alvin Mclean, Diana D. Cardenas, Donna Burgess, Elkan Gamzu

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The current study evaluated under double-blind placebo-controlled conditions, the safety and efficacy of 400 mg pramiracetam sulphate TID in treating memory and other cognitive problems of males who have sustained brain injuries. The results of the study indicate that subject performance in measures of memory, especially delayed recall, evidenced clinically significant improvements after the administration of pramiracetam sulphate as compared to placebo. This improvement was maintained during an 18-month open-trial period on the medication as well as during a 1-month follow-up period after the pramiracetam was discontinued.

Original languageEnglish
Pages (from-to)375-380
Number of pages6
JournalBrain Injury
Volume5
Issue number4
DOIs
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Craniocerebral Trauma
Placebos
Repression (Psychology)
Brain Injuries
Safety
pramiracetam
Hypoxia

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Placebo-controlled study of pramiracetam in Young males with memory and cognitive problems resulting from head injury and anoxia. / Mclean, Alvin; Cardenas, Diana D.; Burgess, Donna; Gamzu, Elkan.

In: Brain Injury, Vol. 5, No. 4, 01.01.1991, p. 375-380.

Research output: Contribution to journalArticle

Mclean, Alvin ; Cardenas, Diana D. ; Burgess, Donna ; Gamzu, Elkan. / Placebo-controlled study of pramiracetam in Young males with memory and cognitive problems resulting from head injury and anoxia. In: Brain Injury. 1991 ; Vol. 5, No. 4. pp. 375-380.
@article{dec0713dd89a4000b0340d56ac51bc90,
title = "Placebo-controlled study of pramiracetam in Young males with memory and cognitive problems resulting from head injury and anoxia",
abstract = "The current study evaluated under double-blind placebo-controlled conditions, the safety and efficacy of 400 mg pramiracetam sulphate TID in treating memory and other cognitive problems of males who have sustained brain injuries. The results of the study indicate that subject performance in measures of memory, especially delayed recall, evidenced clinically significant improvements after the administration of pramiracetam sulphate as compared to placebo. This improvement was maintained during an 18-month open-trial period on the medication as well as during a 1-month follow-up period after the pramiracetam was discontinued.",
author = "Alvin Mclean and Cardenas, {Diana D.} and Donna Burgess and Elkan Gamzu",
year = "1991",
month = "1",
day = "1",
doi = "10.3109/02699059109008110",
language = "English",
volume = "5",
pages = "375--380",
journal = "Brain Injury",
issn = "0269-9052",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Placebo-controlled study of pramiracetam in Young males with memory and cognitive problems resulting from head injury and anoxia

AU - Mclean, Alvin

AU - Cardenas, Diana D.

AU - Burgess, Donna

AU - Gamzu, Elkan

PY - 1991/1/1

Y1 - 1991/1/1

N2 - The current study evaluated under double-blind placebo-controlled conditions, the safety and efficacy of 400 mg pramiracetam sulphate TID in treating memory and other cognitive problems of males who have sustained brain injuries. The results of the study indicate that subject performance in measures of memory, especially delayed recall, evidenced clinically significant improvements after the administration of pramiracetam sulphate as compared to placebo. This improvement was maintained during an 18-month open-trial period on the medication as well as during a 1-month follow-up period after the pramiracetam was discontinued.

AB - The current study evaluated under double-blind placebo-controlled conditions, the safety and efficacy of 400 mg pramiracetam sulphate TID in treating memory and other cognitive problems of males who have sustained brain injuries. The results of the study indicate that subject performance in measures of memory, especially delayed recall, evidenced clinically significant improvements after the administration of pramiracetam sulphate as compared to placebo. This improvement was maintained during an 18-month open-trial period on the medication as well as during a 1-month follow-up period after the pramiracetam was discontinued.

UR - http://www.scopus.com/inward/record.url?scp=0026043645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026043645&partnerID=8YFLogxK

U2 - 10.3109/02699059109008110

DO - 10.3109/02699059109008110

M3 - Article

C2 - 1786500

AN - SCOPUS:0026043645

VL - 5

SP - 375

EP - 380

JO - Brain Injury

JF - Brain Injury

SN - 0269-9052

IS - 4

ER -